Overview

Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD). Healthy volunteers and patients with atopic dermatitis will be studied.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Pimecrolimus
Tacrolimus